These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 31410021)

  • 1. Oridonin overcomes the gemcitabine resistant PANC-1/Gem cells by regulating GST pi and LRP/1 ERK/JNK signalling.
    Wang B; Shen C; Li Y; Zhang T; Huang H; Ren J; Hu Z; Xu J; Xu B
    Onco Targets Ther; 2019; 12():5751-5765. PubMed ID: 31410021
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gem-citabine by regulating the PI3K/Akt/mTOR signaling pathway.
    Zhou HY; Yao XM; Chen XD; Tang JM; Qiao ZG; Wu XY
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10283-10289. PubMed ID: 31841183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ribosomal associated protein hnRNP D in gemcitabine-resistant pancreatic cancer.
    Wang C; Huang H
    Biochem Biophys Res Commun; 2021 Nov; 579():181-187. PubMed ID: 34624736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oridonin enhances the anti-tumor activity of gemcitabine towards pancreatic cancer by stimulating Bax- and Smac-dependent apoptosis.
    Liu DL; Bu HQ; Wang WL; Luo H; Cheng BN
    Transl Cancer Res; 2020 Jul; 9(7):4148-4161. PubMed ID: 35117784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing of IGHG1 reverses the resistance of pancreatic cancer to multidrug chemotherapy by modulating autophagy.
    Tian Y; Han W; Fu L; Lv K; Zhou X
    Environ Toxicol; 2023 Aug; 38(8):1835-1845. PubMed ID: 37186415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A novel chemo-resistant gene MSX2 discovered by establishment of two pancreatic cancer drug resistant cell lines JF305/CDDP and PANC-1/GEM].
    Yuan W; Sui CG; Ma X; Ma J
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):330-334. PubMed ID: 29860758
    [No Abstract]   [Full Text] [Related]  

  • 7. Thymoquinone affects the gemcitabine sensitivity of pancreatic cancer by regulating collagen via hypoxia inducible factor-1α.
    Zhao Z; Liu L; Chen H; Li S; Guo Y; Hou X; Yang J
    Front Pharmacol; 2023; 14():1138265. PubMed ID: 37324458
    [No Abstract]   [Full Text] [Related]  

  • 8. microRNA-218 promotes gemcitabine sensitivity in human pancreatic cancer cells by regulating HMGB1 expression.
    Liu Z; Du R; Long J; Guo K; Ge C; Bi S; Xu Y
    Chin J Cancer Res; 2015 Jun; 27(3):267-78. PubMed ID: 26157323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triptolide enhances the sensitivity of pancreatic cancer PANC-1 cells to gemcitabine by inhibiting TLR4/NF-κB signaling.
    Ma JX; Sun YL; Yu Y; Zhang J; Wu HY; Yu XF
    Am J Transl Res; 2019; 11(6):3750-3760. PubMed ID: 31312385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of lncRNA AFAP1-AS1 by oridonin inhibits the epithelial-to-mesenchymal transition and proliferation of pancreatic cancer cells.
    Lou S; Xu J; Wang B; Li S; Ren J; Hu Z; Xu B; Luo F
    Acta Biochim Biophys Sin (Shanghai); 2019 Aug; 51(8):814-825. PubMed ID: 31314060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of serine/threonine protein phosphatase 5 enhances gemcitabine sensitivity by promoting apoptosis in pancreatic cancer cells
    Zhu J; Ji Y; Yu Y; Jin Y; Zhang X; Zhou J; Chen Y
    Oncol Lett; 2018 Jun; 15(6):8761-8769. PubMed ID: 29805615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-delivery of gemcitabine and Triapine by calcium carbonate nanoparticles against chemoresistant pancreatic cancer.
    Zhao Y; Zheng Y; Zhu Y; Ding K; Zhou M; Liu T
    Int J Pharm; 2023 Apr; 636():122844. PubMed ID: 36925025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [X-linked inhibitor of apoptosis protein (XIAP) and Survivin suppression on human pancreatic cancer cells Panc-1 proliferation and chemosensitivety].
    Zai HY; Yi XP; Li YX; You XY; Cao LP; Liu H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):242-9. PubMed ID: 23591345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oridonin inhibition and miR‑200b‑3p/ZEB1 axis in human pancreatic cancer.
    Gui Z; Luo F; Yang Y; Shen C; Li S; Xu J
    Int J Oncol; 2017 Jan; 50(1):111-120. PubMed ID: 27878247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experimental study on anti-pancreatic cancer effect of oridonin].
    Wang H; Wang YF; Liu TG; Xiang XL; Huang SL
    Zhong Yao Cai; 2014 Jul; 37(7):1230-3. PubMed ID: 25566662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CircHIPK3 Promotes Gemcitabine (GEM) Resistance in Pancreatic Cancer Cells by Sponging miR-330-5p and Targets RASSF1.
    Liu Y; Xia L; Dong L; Wang J; Xiao Q; Yu X; Zhu H
    Cancer Manag Res; 2020; 12():921-929. PubMed ID: 32104074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic analysis of gemcitabine-induced drug resistance in pancreatic cancer cells.
    Chen YW; Liu JY; Lin ST; Li JM; Huang SH; Chen JY; Wu JY; Kuo CC; Wu CL; Lu YC; Chen YH; Fan CY; Huang PC; Law CH; Lyu PC; Chou HC; Chan HL
    Mol Biosyst; 2011 Nov; 7(11):3065-74. PubMed ID: 21894339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine-Loaded Albumin Nanoparticle Exerts An Antitumor Effect on Gemcitabine-Resistant Pancreatic Cancer Cells Induced by MDR1 and MRP1 Overexpression in Vitro.
    Kong L; Du J; Gu J; Deng J; Guo Y; Tao B; Jin C; Fu D; Li J
    Front Surg; 2022; 9():890412. PubMed ID: 35656085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-Delivery of Gemcitabine and Mcl-1 SiRNA via Cationic Liposome-Based System Enhances the Efficacy of Chemotherapy in Pancreatic Cancer.
    Wang Y; Gao F; Jiang X; Zhao X; Wang Y; Kuai Q; Nie G; He M; Pan Y; Shi W; Ren S; Yu Q
    J Biomed Nanotechnol; 2019 May; 15(5):966-978. PubMed ID: 30890228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic stellate cell-induced gemcitabine resistance in pancreatic cancer is associated with LDHA- and MCT4-mediated enhanced glycolysis.
    Amrutkar M; Berg K; Balto A; Skilbrei MG; Finstadsveen AV; Aasrum M; Gladhaug IP; Verbeke CS
    Cancer Cell Int; 2023 Jan; 23(1):9. PubMed ID: 36658582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.